本文選題：藥價談判　切入點(diǎn)：專利藥　出處：《上海醫(yī)藥工業(yè)研究院》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：多年以來,我國藥品價格虛高現(xiàn)象屢見不鮮,尤其是進(jìn)口的專利藥品由于臨床療效突出,加之缺乏市場競爭,在我國長期處于壟斷地位,藥品價格普遍居高不下。專利藥品由于具有一定的市場保護(hù)期限,無法與普通藥品一樣,以市場競爭形成藥品價格,因此,需要采取統(tǒng)一談判的方式,將專利藥品價格控制在合理的區(qū)間范圍內(nèi),談判模式形成專利藥價格也是國際通行的方式。目前我國的藥品價格談判工作尚處于初探階段,沒有形成成熟系統(tǒng)的藥品價格談判模式。為了給國家談判工作中品種的選擇提供一定參考,最終完善我國藥價談判的制度體系,本文立足于國家藥品價格談判的品種,從專利藥品種角度出發(fā),深入分析專利藥產(chǎn)品的特征和使用現(xiàn)狀,首先對專利藥產(chǎn)品提出遴選原則和篩選辦法,其次對專利藥品相關(guān)影響因素進(jìn)行具體分析,篩選出重要的評價指標(biāo),賦予相對合理的權(quán)重,并通過首批談判品種對結(jié)果進(jìn)行驗(yàn)證,最終形成專利藥價格談判品種的評價體系。本文的研究方法有六種,分別是專家咨詢、文獻(xiàn)調(diào)研、調(diào)查問卷、實(shí)證驗(yàn)證、定性分析和定量統(tǒng)計分析法。通過對專利藥利益相關(guān)方的分析,確定了專利藥談判品種的五大遴選原則;并從疾病、品種和企業(yè)三個角度闡述了專利藥談判品種遴選的具體方法;最后從不同角度分析專利藥談判品種相關(guān)指標(biāo),形成了5個維度的初級指標(biāo),14個定性指標(biāo)以及眾多觀測指標(biāo)。通過問卷調(diào)查和專家咨詢的方式對二級指標(biāo)賦予一定權(quán)重,其次對指標(biāo)體系進(jìn)行實(shí)證研究,根據(jù)觀測指標(biāo)對專利藥產(chǎn)品進(jìn)行具體的衡量和評價,形成專利藥產(chǎn)品評價的最終結(jié)果。通過首批談判的三個品種,對評價體系進(jìn)行進(jìn)一步的驗(yàn)證,三個品種評價的結(jié)果均為有談判價值,表明指標(biāo)體系較為合理。本文的創(chuàng)新點(diǎn)主要在于選題新穎,研究內(nèi)容具有實(shí)際意義,研究成果具有前瞻性。國家藥品價格談判正處于首批試點(diǎn)階段,是當(dāng)前國家的熱點(diǎn)話題,本文通過定性結(jié)合定量的方法,理論結(jié)合實(shí)證的方法,以及專家咨詢的方法,針對談判品種進(jìn)行深入研究。
[Abstract]:For many years, the phenomenon of false high drug prices has been common in our country, especially because of the outstanding clinical efficacy of imported patented drugs and the lack of market competition, they have been in a monopoly position for a long time in our country. Drug prices are generally high. Because patent drugs have a certain period of market protection, they are unable to form drug prices in the same way as ordinary medicines by market competition. Therefore, it is necessary to adopt a unified negotiation method. To control the price of patent drugs within a reasonable range, the negotiation mode is also a common mode in the world. At present, the negotiation of drug prices in our country is still in the preliminary stage. In order to provide a certain reference for the selection of varieties in the national negotiations and finally perfect the institutional system of drug price negotiations in China, this paper is based on the varieties of the national drug price negotiations. From the point of view of the variety of patent drugs, the characteristics and current situation of patent drug products are analyzed in depth. Firstly, the selection principles and screening methods of patent drug products are put forward. Secondly, the related factors of patent drugs are analyzed concretely. The important evaluation index is screened out, the relative reasonable weight is given, and the result is verified by the first batch of negotiated varieties. Finally, the evaluation system of the patented drug price negotiation variety is formed. There are six kinds of research methods in this paper, which are expert consultation, respectively. Literature investigation, questionnaire, empirical verification, qualitative analysis and quantitative statistical analysis. Through the analysis of the stakeholders of patent drugs, the paper determines the five principles of selection of patent drugs negotiated varieties; and from the disease, This paper expounds the specific methods of variety selection in patent drug negotiation from three angles: variety and enterprise. Finally, it analyzes the related indexes of patent drug negotiation from different angles. It forms five dimensions of primary indicators, 14 qualitative indicators and many observation indicators. Through questionnaires and expert consultation, the secondary indicators are given a certain weight, and then the index system is empirically studied. According to the measurement and evaluation of the patent drug products, the final results of the patent drug product evaluation are formed. The evaluation system is further verified through the first three negotiated varieties. The results of the evaluation of the three varieties are of negotiation value, indicating that the index system is reasonable. The innovation of this paper is mainly due to the novelty of the selected topics and the practical significance of the research contents. The research results are forward-looking. The national drug price negotiations are in the first pilot stage, which is a hot topic in our country. This paper combines qualitative and quantitative methods, theoretical and empirical methods, as well as expert consultation methods. Carry on the thorough research to the negotiation variety.
【學(xué)位授予單位】：上海醫(yī)藥工業(yè)研究院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R95

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李國鋒;鄭文華;本刊編輯部;張思樂;;天價專利藥,不道德?[J];家庭藥師;2011年07期

2 葉露;武瑞雪;;專利藥的定價與補(bǔ)償國際比較[J];中國醫(yī)療保險;2009年04期

3 張方;朱越;;加拿大專利藥品政府管制定價政策介紹[J];中國藥物經(jīng)濟(jì)學(xué);2012年01期

4 沈路;“仿”好到期專利藥[J];醫(yī)藥世界;2004年12期

5 沈晗;徐懷伏;;發(fā)展中國家專利藥品高價問題及對策研究[J];上海醫(yī)藥;2008年09期

6 姜成菊;;我國過期專利藥與仿制藥價格及使用現(xiàn)狀分析[J];首都醫(yī)藥;2013年22期

7 孫文;;制藥業(yè):環(huán)境變了,商業(yè)模式一定要變[J];中國衛(wèi)生產(chǎn)業(yè);2006年03期

8 林坤;;新政時期:藥業(yè)上演仿制暗戰(zhàn)[J];中國衛(wèi)生產(chǎn)業(yè);2007年06期

9 ;加拿大 專利藥品生產(chǎn)和價格控制制度[J];醫(yī)藥世界;2007年05期

10 江一帆;藥品創(chuàng)新與仿制的對弈[J];首都醫(yī)藥;2002年07期

相關(guān)重要報紙文章 前10條

1 中國藥科大學(xué)國際醫(yī)藥商學(xué)院 沈晗　徐懷伏;專利藥品高價的因果及對策[N];中國醫(yī)藥報;2009年

2 沈陽藥科大學(xué)工商管理學(xué)院副教授 張方;對專利藥價專立監(jiān)管[N];醫(yī)藥經(jīng)濟(jì)報;2012年

3 易瑤;政府統(tǒng)一制定專利藥價格[N];健康報;2008年

4 賈戈;在國際比較中調(diào)控藥價[N];中國經(jīng)濟(jì)導(dǎo)報;2008年

5 新訊;美國——專利藥失去保護(hù)堪喜[N];醫(yī)藥經(jīng)濟(jì)報;2000年

6 顧潤豐　孫長龍;企業(yè)應(yīng)如何延長專利藥品保護(hù)期？[N];中國知識產(chǎn)權(quán)報;2012年

7 沈陽藥科大學(xué)副教授 張方;管控韁繩牽住高價專利藥[N];醫(yī)藥經(jīng)濟(jì)報;2012年

8 本報記者 段玉清;專利藥大量到期 四川藥企等來機(jī)遇[N];四川日報;2013年

9 本報記者 張旭;專利藥品利潤率與可及性[N];中國醫(yī)藥報;2014年

10 駐京記者 金豐杰;禮來與諾華的“中國信心”[N];醫(yī)藥經(jīng)濟(jì)報;2003年

相關(guān)博士學(xué)位論文 前1條

1 劉嬋;制藥企業(yè)的知識產(chǎn)權(quán)運(yùn)用行為與政府政策分析[D];東北財經(jīng)大學(xué);2014年

相關(guān)碩士學(xué)位論文 前2條

1 榮雪菁;中國專利藥品價格比較及藥品談判采購研究[D];山東大學(xué);2017年

2 陳姣姣;論我國專利藥與仿制藥規(guī)制體系完善[D];華東政法大學(xué);2014年

，

本文編號：1587900